By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

S*Bio 

10 Science Park Road
#03-18 The Alpha
Singapore Science Park #2    117684  Singapore
Phone: 65-6827-5000 Fax: 65-6827-5005


SEARCH JOBS


Industry
Biotechnology






Company News
Week in Review: Singapore's S*Bio Sells Cancer Drug to US Pharma 8/13/2012 9:04:13 AM
S*Bio of Singapore Sells Cancer Drug Rights to MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) for $75 Million 8/10/2012 2:24:37 PM
Cell Therapeutics, Inc. (CTIC) Pays $30 Million in Cash and Stock for S*Bio’s Selective JAK2 Inhibitor 4/19/2012 7:27:57 AM
S*Bio's Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies For Patients with Myelofibrosis (MF) 11/22/2011 11:45:27 AM
S*Bio to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF) 10/25/2011 11:28:21 AM
Additional Data From Multiple Phase 1 and 2 Studies of S*Bio's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF) 6/1/2011 9:35:35 AM
S*Bio Restructures $550 Million Agreement With Onyx Pharmaceuticals, Inc. (ONXX) for JAK2 Inhibitor Program 5/4/2011 7:15:32 AM
S*Bio Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies 4/14/2011 12:39:41 PM
S*Bio's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2/28/2011 9:04:02 AM
S*Bio's Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies 12/7/2010 11:09:54 AM
1234
//-->